Search

IntroductionThe prevalence of non-communicable diseases, such as diabetes and cardiovascular diseases,is increasing globally, posing a significant challenge for individuals, communities, andsocieties worldwide. Addressing this burden requires a multifaceted approach thatencompasses not only primary prevention and early detection but also patient education, aswell as comprehensive care coordination. The pharmacy profession has evolved significantlyin recent decades, shifting from a traditional role of delivering medication to more clinicalactivities. Pharmacists could take a more active role as primary care team members,leveraging their accessibility and expertise, in identifying, counselling, and referring patientswith previously undiagnosed conditions. International evidence has demonstrated thebenefit of pharmacy-led screening services. However, translating the findings into practicecan be challenging due to the variability of regulatory environment and practices betweencountries.Objectives of the thesisThis thesis intends to explore the extent to which community pharmacists can contribute toscreening for diabetes and cardiovascular diseases in Belgium. Through different studies, itaims to gain a deeper understanding of the feasibility of delivering a risk assessment incommunity pharmacies, to gather the perceptions of the stakeholders, as well as thecontextual factors that may facilitate or hinder a successful implementation withincommunity pharmacies of pharmacist-led services of this nature. Furthermore, the researchaims to develop tools that can support pharmacists in providing a diabetes and cardiovasculardisease risk assessment service.MethodsFirstly, to explore the feasibility of offering a risk assessment service for diabetes andcardiovascular diseases in the Brussels Capital Region, three qualitative studies wereconducted with 17 pharmacists, 14 patients and 14 general practitioners. Secondly, a mixedmethod was used following the RE-AIM framework to evalu, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

SCOPUS: ed.j, info:eu-repo/semantics/published

Introduction:Asthma and chronic obstructive pulmonary disease (COPD) are common chronic diseases. According to the World Health Organization, asthma is one of the most common chronic diseases in children, and COPD is the third leading cause of death worldwide. Early detection and appropriate treatment can significantly improve health outcomes.Objectives:This thesis focused on medication adherence in asthma and COPD. First, we aimed to assess the consumption of asthma medications prescribed to children in Belgium. Second, we aimed to assess adherence and persistence with inhaled medications for the chronic treatment of asthma and COPD and to evaluate the factors influencing adherence. Factors examined were gender, age, device type, BIM status, employment status, region of residence, and the new medicines service (NMS) offered by pharmacists. Thirdly, we aimed to determine the expectations of COPD patients and healthcare practitioners towards a mobile application or web platform and to identify potential barriers or facilitators to the use of such digital tools. In addition, we sought to evaluate the current state of collaboration between healthcare practitioners and the impact of a technological tool.Methods:To assess the consumption of asthma medication in children in Belgium, a retrospective study was conducted using anonymized administrative data from Independent Health Insurance Funds for the period 2013-2018. For the second objective, we conducted a retrospective study on the National Institute for Health and Disability Insurance (NIHDI) database containing dispensing data for inhaled medications for the treatment of asthma and COPD from 2013 to 2016. Therapeutic adherence was assessed using the continuous multiple-interval measures of medication availability (CMA). This part was completed by a similar retrospective study on an Independent Health Insurance Funds database, enabling the analysis of new factors influencing adherence for the period 2013 to 2018. Fin, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

N-glycosylation is one of the most prominent post-translational modifications (PTM) of glycoproteins. Antibodies are glycosylated proteins, and the alteration of this modification may influence its function, stability and half-life. Importantly, antibodies play a central role in humoral immunity against pathogens, particularly immunoglobulin G (IgG), which is a key effector of the humoral immune response.For this reason, the first part of this PhD work was dedicated to the development and validation of a reliable, sensitive and robust analytical method for the characterization of IgG N-glycans. To achieve this aim, procainamide was used for the labeling of the glycans. The analytical method is based on two steps: first an enrichment step using online solid phase extraction (SPE) with hydrophilic interaction liquid chromatography (HILIC) chemistry, then, a separation step using the same chemistry (HILIC) coupled to fluorescence (FLD) and mass spectrometry (MS) detectors Several parameters were optimized using an experimental design. After that, a validation process was performed, and repeatability, precision and stability were confirmed. NIST standard (reference material 8671, monoclonal antibodies), Trixuma© (biosimilar) and MabThera© (bio original) as well as commercial kits, were also used for the validation to compare our findings to the literature.After its validation, we decided to evaluate this method for the characterization of IgG N-glycans in patients with different diseases. Given the pandemic situation, the first studied disease was the COVID-19 with a group of patients suffering from severe COVID-19 and hospitalized in intensive care unit (ICU). Those patients were divided into two groups according to their clinical outcome (survival or death) and compared to healthy volunteers and ICU hospitalized patients suffering from sepsis. Our data indicated that a specific bisecting N-glycan, FA2B, is a potential biomarker of the mortality risk. The increase of F, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

Aliphatic hydroxamic acids (HA) with varying numbers of carbon atoms, C2, C6, C8, C10, C12 and C17, and corresponding Fe(II), Fe(III), Ni(II), Cu(II) and Zn(II) complexes have been synthesized and characterized by various methods, including structural determination by single crystal X-ray diffraction and theoretical calculations. The biological activities of HA and their complexes have been assessed on a panel of pathogens, including eight bacteria strains and one fungus. The C12 aliphatic HA displayed the lowest minimum inhibitory concentrations (MIC) towards several microbial strains and a selective antifungal activity. This antifungal selectivity was further improved considering the Ni(II), Cu(II) and Zn(II) complexes of C12 HA showed higher IC50 values, thus less impact on the SiHa human cell line viability. This work warrants further investigation to understand the underlying mechanism of action and potential biological applications of HA and the derived metal complexes.

Background To support the COVID‐19 pandemic response, many countries, including Belgium, implemented baseline genomic surveillance (BGS) programs aiming to early detect and characterize new SARS‐CoV‐2 variants. In parallel, Belgium maintained a sentinel network of six hospitals that samples patients with severe acute respiratory infections (SARI) and integrated SARS‐CoV‐2 detection within a broader range of respiratory pathogens. We evaluate the ability of the SARI surveillance to monitor general trends and early signals of viral genetic evolution of SARS‐CoV‐2 and compare it with the BGS as a reference model. Methods Nine‐hundred twenty‐five SARS‐CoV‐2 positive samples from patients fulfilling the Belgian SARI definition between January 2020 and December 2022 were sequenced using the ARTIC Network amplicon tiling approach on a MinION platform. Weekly variant of concern (VOC) proportions and types were compared to those that were circulating between 2021 and 2022, using 96,251 sequences of the BGS. Results SARI surveillance allowed timely detection of the Omicron (BA.1, BA.2, BA.4, and BA.5) and Delta (B.1.617.2) VOCs, with no to 2 weeks delay according to the start of their epidemic growth in the Belgian population. First detection of VOCs B.1.351 and P.1 took longer, but these remained minor in Belgium. Omicron BA.3 was never detected in SARI surveillance. Timeliness could not be evaluated for B.1.1.7, being already major at the start of the study period. Conclusions Genomic surveillance of SARS‐CoV‐2 using SARI sentinel surveillance has proven to accurately reflect VOCs detected in the population and provides a cost‐effective solution for long‐term genomic monitoring of circulating respiratory viruses., SCOPUS: ar.j, info:eu-repo/semantics/published

Coronavirus Disease 2019 (COVID-19) vaccination has resulted in excellent protection against fatal disease, including in older adults. However, risk factors for post-vaccination fatal COVID-19 are largely unknown. We comprehensively studied three large nursing home outbreaks (20-35% fatal cases among residents) by combining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) aerosol monitoring, whole-genome phylogenetic analysis and immunovirological profiling of nasal mucosa by digital nCounter transcriptomics. Phylogenetic investigations indicated that each outbreak stemmed from a single introduction event, although with different variants (Delta, Gamma and Mu). SARS-CoV-2 was detected in aerosol samples up to 52 d after the initial infection. Combining demographic, immune and viral parameters, the best predictive models for mortality comprised IFNB1 or age, viral ORF7a and ACE2 receptor transcripts. Comparison with published pre-vaccine fatal COVID-19 transcriptomic and genomic signatures uncovered a unique IRF3 low/IRF7 high immune signature in post-vaccine fatal COVID-19 outbreaks. A multi-layered strategy, including environmental sampling, immunomonitoring and early antiviral therapy, should be considered to prevent post-vaccination COVID-19 mortality in nursing homes., 0, SCOPUS: ar.j, info:eu-repo/semantics/published

Hydroxamic acid (HA) derivatives display antibacterial and antifungal activities. HA with various numbers of carbon atoms (C2, C6, C8, C10, C12 and C17), complexed with different metal ions, including Fe(II/III), Ni(II), Cu(II) and Zn(II), were evaluated for their antimycobacterial activities and their anti-biofilm activities. Some derivatives showed antimycobacterial activities, especially in biofilm growth conditions. For example, 20-100 µM of HA10Fe2, HA10FeCl, HA10Fe3, HA10Ni2 or HA10Cu2 inhibited Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium marinum biofilm development. HA10Fe2, HA12Fe2 and HA12FeCl could even attack pre-formed Pseudomonas aeruginosa biofilms at higher concentrations (around 300 µM). The phthiocerol dimycocerosate (PDIM)-deficient Mycobacterium tuberculosis H37Ra was more sensitive to the ion complexes of HA compared to other mycobacterial strains. Furthermore, HA10FeCl could increase the susceptibility of Mycobacterium bovis BCG to vancomycin. Proteomic profiles showed that the potential targets of HA10FeCl were mainly related to mycobacterial stress adaptation, involving cell wall lipid biosynthesis, drug resistance and tolerance and siderophore metabolism. This study provides new insights regarding the antimycobacterial activities of HA and their complexes, especially about their potential anti-biofilm activities., SCOPUS: ar.j, info:eu-repo/semantics/published

Les infections microbiennes causées par des agents pathogènes résistants aux thérapies sont en hausse dans le monde. Ce problème touche non seulement les pays développés mais surtout les pays en voie de développement. Dans les milieux ruraux, les habitants n’ont pas accès aux conditions sanitaires appropriées. La majorité des hôpitaux de l’Afrique sub-saharienne sont cités parmi les plus faibles du monde en termes de qualité de soins et de moyens disponibles. La prolifération des officines pharmaceutiques « clandestines » qui échappent au contrôle des États minés par la corruption et le laxisme est un signe de la difficulté d’apporter des solutions satisfaisantes aux problèmes de la population. Cet état de fait entraine un trafic frauduleux et un large usage de « faux médicaments » par la population. Le manque de traitements efficaces est l’une des causes des maladies infectieuses présentant une résistance aux antibiotiques. Face à ces fléaux, il est nécessaire de développer de nouveaux agents antimicrobiens.Les acides hydroxamiques (AH) présentent diverses propriétés biologiques contre les bactéries, les champignons, les virus et les cellules cancéreuses. Ils sont aussi de puissants inhibiteurs d’enzymes tels que les hydrolases, l’uréase, la tyrosinase, l’élastase, l’aminopeptidase, les peroxydases, les métalloprotéinases, les histones déacétylases, la peptide déformylase et les anhydrases carboniques. L'activité antimicrobienne des AH convertis en leurs chélates métalliques est améliorée par rapport aux composés non-complexés. La fonction hydroxamate est souvent décrite comme étant à l’origine de l’activité biologique. Cependant, la lipophilie et le type de métal de coordination dans les complexes pourraient être des éléments importants influençant les activités antimicrobiennes de ces composés chimiques.C’est dans cette optique que nous avons synthétisé et caractérisé quarante-deux composés dont six AH et trente-six complexes de Fe (II/III), de Ni (II), de Cu (II, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

info:eu-repo/semantics/published

Aliphatic hydroxamic acids (HA) with varying numbers of carbon atoms, C2, C6, C8, C10, C12 and C17, and corresponding Fe(II), Fe(III), Ni(II), Cu(II) and Zn(II) complexes have been synthesized and characterized by various methods, including structural determination by single crystal X-ray diffraction and theoretical calculations. The biological activities of HA and their complexes have been assessed on a panel of pathogens, including eight bacteria strains and one fungus. The C12 aliphatic HA displayed the lowest minimum inhibitory concentrations (MIC) towards several microbial strains and a selective antifungal activity. This antifungal selectivity was further improved considering the Ni(II), Cu(II) and Zn(II) complexes of C12 HA showed higher IC50 values, thus less impact on the SiHa human cell line viability. This work warrants further investigation to understand the underlying mechanism of action and potential biological applications of HA and the derived metal complexes., SCOPUS: ar.j, info:eu-repo/semantics/published

From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information. A proposal to harmonize reporting of test results was drafted by the National Reference Centre (NRC) UZ/KU Leuven, distinguishing four categories of positivity based on RNA copies/mL. Pre-quantified control material was shipped to 124 laboratories with instructions to setup a standard curve to define thresholds per assay. For each assay, the mean Ct value and corresponding standard deviation was calculated per target gene, for the three concentrations (10, 10 and 10 copies/mL) that determine the classification. The results of 17 assays are summarized. This harmonization effort allowed to ensure that all Belgian laboratories would report positive PCR results in the same semi-quantitative manner to clinicians and to the national database which feeds contact tracing interventions.

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir., SCOPUS: re.j, info:eu-repo/semantics/published

We disclose novel amphiphilic ruthenium and osmium complexes that auto-assemble into nanomedicines with potent antiproliferative activity by inhibition of mitochondrial respiration. The self-assembling units were rationally designed from the [M(p-cymene)(1,10-phenanthroline)Cl]PF6 motif (where M is either RuII or OsII) with an appended C16 fatty chain to achieve high cellular activity, nano-assembling and mitochondrial targeting. These amphiphilic complexes block cell proliferation at the sub-micromolar range and are particularly potent towards glioblastoma neurospheres made from patient-derived cancer stem cells. A subcutaneous mouse model using these glioblastoma stem cells highlights one of our C16 OsII nanomedicines as highly successful in vivo. Mechanistically, we show that they act as metabolic poisons, strongly impairing mitochondrial respiration, corroborated by morphological changes and damage to the mitochondria. A genetic strategy based on RNAi gave further insight on the potential involvement of microtubules as part of the induced cell death. In parallel, we examined the structural properties of these new amphiphilic metal-based constructs, their reactivity and mechanism., info:eu-repo/semantics/published

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir., info:eu-repo/semantics/published

OBJECTIVES : The strains of HBV circulating among blood donors in Lubumbashi, Democratic Republic of Congo (DRC), are not yet characterized. The purpose of this study was to determine seroprevalence, changes in biochemical parameters during HBV infection and molecular characterization of HBV in blood donors in Lubumbashi. METHODS : The detection of HBsAg was carried out by rapid diagnostic test then confirmed by the Liaison XL® Quant HBsAg technique. PCR targeting the P gene was carried out on LightCycler® 96 and genotyping by the sequencing technique on ABI 3500. RESULTS : The seroprevalence was 7.9%. The genotypes E (53.1%), A (41.8%), A3/E (3.8%), A1/E (1.3%) and some drug resistance mutations were identified. Disturbances of HDL-cholesterol, direct bilirubin, transaminases (ASAT and ALAT), PAL, GGT and albumin have been observed in HBsAg positive blood donors. CONCLUSION : The results of our study indicated that Lubumbashi is in a region with high endemicity for HBV and report for the first time HBV of genotypes A, E, A1/E and A3/E. They highlight the need to implement strategies to improve transfusion safety in blood transfusion centers and hospital blood banks in Lubumbashi in order to reduce HBV infection in recipients. They could also contribute to the implementation of treatment strategies and the development of mapping of circulating HBV genotypes in the DRC., [Aspects épidémiologiques et caractérisation moléculaire du virus de l’hépatite B chez les donneurs de sang à Lubumbashi, République démocratique du Congo] OBJECTIFS : Les souches du virus de l’hépatite B (VHB), circulant parmi les donneurs de sang à Lubumbashi, en République démocratique du Congo (RDC), ne sont pas encore caractérisées. Le but de cette étude était de déterminer la séroprévalence et les changements des paramètres biochimiques au cours de l’infection par le VHB et la caractérisation moléculaire du VHB chez les donneurs de sang à Lubumbashi. METHODES : La détection de l’AgHBs a été réalisée par le test de diagnostic rapide, puis confirmée par la technique Liaison XL® Quant HBsAg. La PCR ciblant le gène P a été réalisée sur LightCycler® 96 et le génotypage par la technique de séquençage sur ABI 3500. RESULTATS : La séroprévalence était de 7,9 %. Les génotypes E (53,1 %), A (41,8 %), A3/E (3,8 %), A1/E (1,3 %) et certaines mutations de résistance aux médicaments ont été identifiées. Des perturbations du cholestérol HDL, de la bilirubine directe, des transaminases (ASAT et ALAT), de la PAL, de la GGT et de l’albumine ont été observées chez des donneurs de sang AgHBs positif. CONCLUSION : Les résultats de notre étude avaient indiqué que Lubumbashi se trouve dans une région de forte endémicité pour le VHB et rapportent, pour la première fois, le VHB des génotypes A, E, A1/E et A3/E. Ils soulignent la nécessité de mettre en œuvre des stratégies pour améliorer la sécurité transfusionnelle dans les centres de transfusion sanguine et les banques de sang des hôpitaux de Lubumbashi, afin de réduire l’infection par le VHB chez les receveurs. Ils pourraient également contribuer à la mise en œuvre de stratégies de traitement au développement de la cartographie des génotypes circulants en RDC.

Myeloperoxidase participates in innate immune defense mechanism through formation of microbicidal reactive oxidants and diffusible radical species. A unique activity is its ability to use chloride as a cosubstrate with hydrogen peroxide to generate chlorinating oxidants such as hypochlorous acid, a potent antimicrobial agent. However, chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. This has attracted considerable interest in the development of therapeutically useful MPO inhibitors. Today, based on the profound knowledge of structure and function of MPO and its biochemical and biophysical differences with the other homologous human peroxidases, various rational and high-throughput screening attempts were performed in developing specific irreversible and reversible inhibitors. The most prominent candidates as well as MPO inhibitors already studied in clinical trials are introduced and discussed., info:eu-repo/semantics/published, 1

Myeloperoxidase participates in innate immune defense mechanism through formation of microbicidal reactive oxidants and diffusible radical species. A unique activity is its ability to use chloride as a cosubstrate with hydrogen peroxide to generate chlorinating oxidants such as hypochlorous acid, a potent antimicrobial agent. However, chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. This has attracted considerable interest in the development of therapeutically useful MPO inhibitors. Today, based on the profound knowledge of structure and function of MPO and its biochemical and biophysical differences with the other homologous human peroxidases, various rational and high-throughput screening attempts were performed in developing specific irreversible and reversible inhibitors. The most prominent candidates as well as MPO inhibitors already studied in clinical trials are introduced and discussed., info:eu-repo/semantics/published

En 2021, les cancers sont toujours une des principales causes de mortalité au niveau mondiale. C'est d'une part, une compréhension croissante des phénomènes biologiques liés au développement des cancers et d'autre part, l'évolution des traitements qui nous ont permis d'obtenir et de constamment accroître les taux de guérison et de rémission pour certains types de cancer (ex. cancers du sein, du poumon, du côlon). Mais malgré une pléthore de traitements antitumoraux et l'évolution de techniques médicales aussi bien curatives que diagnostiques, certains cancers sont toujours des maladies difficiles à traiter et restent associés à des prognostiques très négatifs (ex. cancers du pancréas, du cerveau), dès lors le besoin de nouvelles molécules antitumorales est toujours cruellement nécessaire.Ce travail s'inscrit dans ce contexte de développement de nouveaux complexes métalliques possédant des propriétés anticancéreuses ainsi qu'à leur évaluation biologique et à la compréhension de leur mécanisme d'action. L'intérêt des complexes métalliques comme potentiels agents anti-cancéreux a commencé dans les années 60 par la découverte fortuite de la puissante activité antiproliférative du cisplatine. Cette étape a été déterminante et a orienté plus de cinquante années de recherche. De nos jours, les médicaments à base de platine ont toujours une place importante dans l'arsenal thérapeutique anticancéreux, en effet le cisplatine, le carboplatine et l'oxaliplatine sont administrés chez plus de 50% des patients qui reçoivent une chimiothérapie. Néanmoins l'usage des traitements à base des molécules dérivées de platine soulèvent deux problèmes majeurs ;l'apparition d'effets secondaires sévères due au manque de sélectivité pour les cellules tumorales, ainsi que l'émergence de lignées tumorales résistantes à la suite des traitements à base de dérivés de platine. Ceci explique la raison pour laquelle les chercheurs se sont concentrés sur le développement de nouveaux complexes métalliqu, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

Ruthenium (Ru) and osmium (Os) complexes are of sustained interest in cancer research and may be alternative to platinum-based therapy. We detail here three new series of ruthenium and osmium complexes, supported by physico-chemical characterizations, including time-dependent density functional theory, a combined experimental and computational study on the aquation reactions and the nature of the metal-arene bond. Cytotoxic profiles were then evaluated on several cancer cell lines although with limited success. Further investigations were, however, performed on the most active series using a genetic approach based on RNA interference and highlighted a potential multi-target mechanism of action through topoisomerase II, mitotic spindle, HDAC and DNMT inhibition., SCOPUS: ar.j, info:eu-repo/semantics/published

Modified-release oral drug delivery dosage forms are widely used in the pharmaceutical field to overcome all the potential issues imposed by the physiological variabilities of the gastrointestinal tract as well as to maintain drug concentrations within the therapeutic window. In the market, they are available only as solid dosage forms such as capsules or tablets. The development of a liquid oral dosage form with modified-release properties has been keenly awaited. This form could increase the compliance of patients with a swallowing impairment (i.e. paediatric, older or critically ill patients) and, consequently, the efficacy of the therapeutic treatment. In this study, a new technology has been developed that consists of multi-layered particles suspended extemporaneously in a syrup. Omeprazole and budesonide have been employed as model drugs. The coating procedure was optimized to obtain a yield of minimum 90% w/w and a median diameter below 500 µm. Once the final suspension is prepared extemporaneously, it presents sufficient stability to guarantee the administration of multiple doses filled into a syrup bottle and kept for a limited storage time at room temperature (e.g. up to 10 doses to be administered within 10 days)., Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

Introduction: Myeloperoxidase (MPO) is an immune enzyme found in neutrophils and macrophages. It produces the highly oxidative compound HOCl from H2O2 and Cl− ions inside the phagosome of the neutrophil. Leakage of the enzyme outside the cell causes oxidative damages for the biomolecules promoting many inflammatory diseases such as atherosclerosis. Thus, there is a real interest to develop potent inhibitors of MPO as non-steroidal anti-inflammatory agents. This review highlights the several published MPO inhibitors, their activity, and the challenges met during the development of these compounds. Areas covered: This article covers the patent literature published on MPO inhibitors from 2013 to 2019, as well as the potential use of these compounds as therapeutics for inflammatory syndromes, especially that plays an important role in the initiation and progression of atherosclerosis. Expert opinion: To date, many MPO inhibitors with different structures have been studied, many of which have prominent inhibitory activities. Furthermore, the specificity of these drugs offers hope for the targeted therapy of inflammatory syndromes. Although many data have proved that MPO can contribute to several chronic inflammatory syndromes, the usefulness of MPO inhibitors in preventing and treating inflammatory disorders is still under investigation., SCOPUS: re.j, info:eu-repo/semantics/published

Reactive oxygen species (ROS) have been correlated with almost every human disease. Yet clinical exploitation of these hypotheses by pharmacological modulation of ROS has been scarce to nonexistent. Are ROS, thus, irrelevant for disease? No. One key misconception in the ROS field has been its consideration as a rather detrimental metabolic by-product of cell metabolism, and thus, any approach eliminating ROS to a certain tolerable level would be beneficial. We now know, instead, that ROS at every concentration, low or high, can serve many essential signaling and metabolic functions. This likely explains why systemic, nonspecific antioxidants have failed in the clinic, often with neutral and sometimes even detrimental outcomes. Recently, drug development has focused, instead, on identifying and selectively modulating ROS enzymatic sources that in a given constellation cause disease while leaving ROS physiologic signaling and metabolic functions intact. As sources, the family of NADPH oxidases stands out as the only enzyme family solely dedicated to ROS formation. Selectively targeting disease-relevant ROS-related proteins is already quite advanced, as evidenced by several phase II/III clinical trials and the first drugs having passed registration. The ROS field is expanding by including target enzymes and maturing to resemble more and more modern, big data-enhanced drug discovery and development, including network pharmacology. By defining a disease based on a distinct mechanism, in this case ROS dysregulation, and not by a symptom or phenotype anymore, ROS pharmacology is leaping forward from a clinical underperformer to a proof of concept within the new era of mechanism-based precision medicine. SIGNIFICANCE STATEMENT: Despite being correlated to almost every human disease, nearly no ROS modulator has been translated to the clinics yet. Here, we move far beyond the old-fashioned misconception of ROS as detrimental metabolic by-products and suggest 1) novel pharmaco, SCOPUS: ar.j, info:eu-repo/semantics/published

The cytoplasmic tail (CT) of the HIV-2 envelope glycoprotein (Env) includes amino acid (aa) sequences that are similar to lentiviral lytic peptides (LLP) described in other lentiviruses. Within the putative LLP-2 region, we previously observed insertions of 3 or 7 aa in sequences deduced from plasma viral RNA of symptomatic HIV-2-infected individuals. Based on these observations, we reproduced the insertions in a molecular clone to assess their impact on replicative fitness and cell death in vitro. Using a molecular clone of the HIV-2 reference strain, site-directed mutagenesis experiments allowed the generation of plasmids with the insertion LTAI or LQRALTAI in the Env protein. The clone with 7 aa insertion enhanced viral release 8 to 11 times in infected T cells and cell viability was impaired by more than 20%, compared with the wild-type HIV-2 virus. The effect of the 3 aa insertion was milder, with a nonsignificant trend to enhance viral replication and cell death compared with the wild-type virus. Interestingly, the insertions in the Env proteins did not induce a significant increase of viral infectivity, as revealed by the infectivity assay using TZM-bl cells. The insertions in the Env CT observed in vivo from disease progressors may, therefore, be involved in the higher viral load observed in these individuals. This study may open the way to the development of a prognostic marker related to the HIV-2 infection progression.

The Human Immunodeficiency Virus type 2 (HIV-2) is the second etiologic agent causing AIDS (acquired immune deficiency syndrome) in the human host. However, this retrovirus may be considered as an attenuated model of retroviral infection since the HIV-2-infected individuals show a longer asymptomatic phase, lower plasmatic viral loads without antiviral therapy, and do not experience AIDS-like symptoms in 60-70% of cases, in striking contrast with HIV-1-infected patients. HIV-2-positive individuals appear to control the virus replication and the main hypothesis that could explain this phenotype is a strong T cell-mediated immunity and a robust early innate immune response against HIV-2. In this thesis research project, we focus on a host restriction factor involved in the antiviral immune response: BST-2/Tetherin. This interferon (IFN)-inducible protein is able to retain the budding virions at the plasma membrane of the infected cells, and promotes the endocytosis and degradation of the “tethered” viral particle. HIVs have evolved means to counteract BST-2/Tetherin in order to ensure the viral dissemination in the human host. HIV-1 uses the accessory Vpu protein to bind and degrade BST-2/Tetherin, whereas HIV-2 - that lacks Vpu - relies on its envelope (Env) glycoprotein. It has been reported that the HIV-2 envelope glycoproteins bind and remove BST-2 from the cell membrane, but this countermeasure does not result in the degradation of BST-2. HIV-2 Env and BST-2 interact mainly through their ectodomain. However, little was known concerning the domain in the Env protein that can exert this function. During this research project, we first revealed the precise motif within the ectodomain of HIV-2 Env protein involved in the anti-tetherin function. Indeed, we demonstrated that the N659 residue is clearly involved in the antagonism of BST-2/Tetherin. We also showed that the cytoplasmic tail (CT) of the HIV-2 Env protein cooperates in this anti-tetherin function. BST-2/Tet, (BIFA - Sciences biomédicales et pharmaceutiques) -- UCL, 2019

[This corrects the article DOI: 10.1371/journal.pone.0209561.].

Group IV cytosolic phospholipase A2 (cPLA2α) plays a critical role in inflammatory processes. It produces arachidonic acid which is the main source of the pro-inflammatory eicosanoids mediators that are important in innate immune system. In some cases, these pro-inflammatory mediators cause damages to the host tissues and therefore promote autoimmune diseases. Consequently, development of potent inhibitors against cPLA2α could improve the therapy of inflammatory diseases. In the last two decades, intense efforts have been done to find potent cPLA2α inhibitors. Several scaffolds have been developed with the use of structure-activity relationship (SAR) studies, and potent inhibitors have been obtained. The poor absorption of these compounds from intestine was the main challenge for clinical application. This review illustrates the search for cPLA2α inhibitors, their SAR studies and biological effects., SCOPUS: re.j, info:eu-repo/semantics/published

INTRODUCTION: The WHO urges action against the threat posed by HIV drug resistance. It is well known that the sensitivity of Next-Generation Sequencing (NGS) is greater than that of Sanger Sequencing (SS). The objective of this study was to evaluate the performance of the novel NGS HIV-1 drug resistance monitoring system. MATERIALS & METHODS: NGS analyses were performed on 67 plasma samples from HIV-1 infected patients using the Sentosa SQ HIV Genotyping Assay from Vela-Dx. This kit was used on a semi-automated Ion Torrent-based platform. Sequences were compared to those obtained by SS. Samples were analysed in the same and in separate runs. Quality controls (QC) were added to control sequencing processes of protease (PRO), reverse transcriptase (RT) and integrase (INT) regions. RESULTS: Of the 41 analysed samples, 33 (80.5%) had identical drug resistance interpretation reports. Discrepant results were observed for eight samples. Five of them were only detected by NGS and had drug resistance mutations (DRMs) with an allelic frequency below the limit of detection of the SS method (between 6.3 to 20.5%). Two DRMs were only identified using the SS method. The sequences were similar in 98.2% of cases (counting variants as mismatches) and homologous in 99.9% if missed variants. Duplicated samples in a single run were similar in 95.7% (99.9%) of cases. Duplicated samples in two different runs were 98% (100%) homologous. QC results were manually assessed with a score of 340/340 for detection of DRMs in PRO and RT and 100% for INT sequencing. CONCLUSIONS: This is the first preliminary evaluation in Belgium employing the Sentosa SQ HIV Genotyping Assay. The NGS appears to be a promising tool for the detection of DRMs in HIV-1 patients and showed a higher sensitivity compared to SS. Large studies assessing the clinical relevance of low frequency DRMs are needed.

With the emergence of novel and more effective drug therapies, increased importance is being placed upon the methods by which these drugs are being delivered to the body. In conventional drug delivery systems, there is very little control over the release of drug. The effective concentration at the target site can be achieved by intermittent administration of grossly excessive doses, which, often results in constantly, unpredictable variations in plasma concentrations, with the risk of reaching levels below or above the therapeutic range leading to marked side effects. A plethora of formulation strategies mainly based on polymeric/lipid nanoparticles, are described in literature. Even though these systems are therapeutically advantageous in comparison to conventional systems, they remain insensitive to the changing metabolic states of the body although the symptoms of most metabolic diseases follow a rhythmic pattern.A more appropriate and effective approach of managing some of these conditions lies in the chronotherapy. This approach allows for pulsed or self-regulated drug delivery which is adjusted to the staging of biological rhythms, since the onset of certain diseases exhibits strong circadian temporal dependence. In order to reach the objective of mimicking the biophysical and biochemical processes of pathological states, many innovations in material design for drug delivery systems (DDS) that are able to release the therapeutic payload-on-demand were done to release the therapeutic agent only when it is required, according to the physiological need. The development of multidisciplinary research teams has brought huge advantages in the design, fabrication and utilization of such smart systems, especially in the pharmaceutical field. Interestingly, numerous smart polymeric materials exhibit a response to a specific stimulus. A step further, the elaboration of purpose-built monomers can give rise to compounds with tunable sensitivities or multi-stimuli responsi, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

The multiplicity of drug resistant Mycobacterium tuberculosis (Mtb) strains is a growing health issue. New therapies are needed, acting on new targets. The I3-Ag85 was already reported to reduce the amount of trehalose dimycolate lipid of the mycobacterial cell wall. This inhibitor of Ag85C increased the mycobacterial wall permeability. We previously showed that M. tuberculosis strains, even multi-drug resistant and extensively-drug resistant strains, can be susceptible to vancomycin when concomitantly treated with a drug altering the cell envelope integrity. We investigated the effect of the I3-Ag85 on vancomycin susceptibility of M. tuberculosis. Although no synergy was observed, a new target of this drug was discovered: the production of phthiodiolone dimycocerosate (PDIM B)., SCOPUS: ar.j, info:eu-repo/semantics/published

The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants. However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases. Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors. Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening. Starting from a set of 727842 compounds, 28 molecules were selected by this virtual method and tested on MPO in vitro. Twelve out of 28 compounds were found to have an IC50 less than 5 μM. The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, respectively. Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concentration., SCOPUS: ar.j, info:eu-repo/semantics/published

The “Journées Franco-Belges de Pharmacochimie” is a recognized two-day annual meeting on Medicinal Chemistry that is renowned for the advanced science presented, conviviality, and outstanding opportunities for senior and young scientists to exchange knowledge. Abstracts of plenary lectures, oral communications, and posters presented during the meeting are collected in this report., SCOPUS: ar.j, info:eu-repo/semantics/published

info:eu-repo/semantics/published

info:eu-repo/semantics/nonPublished

info:eu-repo/semantics/published

Lung cancer is the deadliest cancer in the world, with a global 5-year survival rate of about 15%. Despite a notable impact of the latest improvements in prevention, screening, detection and staging, the efficacy of conventional treatments is not sufficient and has reached a therapeutic plateau. These conventional treatments involve a combination of surgery, radiotherapy (RT) and chemotherapy (CT). CT is used in almost all stages: in operable and inoperable stages to limit tumour cell invasion and in latest stages as a palliative treatment. Cisplatin is one of the most frequently used and most potent drugs available. It is administered by parenteral route at doses limited by its high and cumulative nephrotoxicity but also by other systemic toxicities (e.g. ototoxicity). Its administration therefore requires many precautions (long hydration procedure, surveillance of the renal function), which mobilize medical personnel. A major limitation of parental CT is the low concentration of drug that successfully reaches the tumour or the metastases. A potential additional modality could be aerosolized CT to localize lung cancer treatment. It has shown a relative local tolerance for cisplatin through preclinical and clinical studies in humans by means of nebulized solutions or liposomal formulations. As a local treatment, aerosolized CT has a clear pharmacokinetic (PK) advantage, as it can increase local exposure while decreasing systemic exposure. However, because CT drugs, such as cisplatin, are active at rather high doses (in the mg range), the duration of administration from nebulizers is very long as it depends on the drug solubility or on drug encapsulation into liposomes. They also pose a high risk of environmental contamination and require HEPA-filtrated hoods during the nebulization procedure. Of all the inhalation devices available to deliver high drug doses, dry powder inhalers (DPIs) were chosen in this work. These were chosen to circumvent the above issues by pro, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

The implementation of dynamic combinatorial libraries allowed the determination of highly active reversible and irreversible inhibitors of myeloperoxidase (MPO) at the nanomolar level. Docking experiments highlighted the interaction between the most active ligands and MPO, and further kinetic studies defined the mode of inhibition of these compounds. Finally, in vivo evaluation showed that one dose of irreversible inhibitors is able to suppress the activity of MPO after inducing inflammation., SCOPUS: ar.j, info:eu-repo/semantics/published

Le laboratoire de Chimie Organique et Photochimie de l’ULB s’est intensivement impliqué dans la recherche portant sur le développement et l’étude de complexes polyazaaromatiques de ruthéniumII. En utilisant des ligands π-déficients tels que le 1,4,5,8-tétraazaphénanthrène (TAP) chélatés au centre métallique de RuII, des propriétés d’oxydo-réduction particulières à l’état excité du complexe peuvent être obtenues. Cette recherche s’est principalement focalisée sur l’étude de complexes de RuII photoréactifs dans un cadre biologique puisque ces complexes sont capables de photoréagir avec le matériel génétique ou les protéines par l’intermédiaire d’un transfert d’électron photo-induit (PET). Cependant, il existe un obstacle majeur à l’utilisation thérapeutique des complexes polyazaaromatiques de RuII, à savoir leur incapacité à traverser d’eux-mêmes la membrane des cellules vivantes. Ce projet vise à développer une stratégie ciblée de vectorisation de ces complexes, ce qui pourrait permet d’administrer l’agent thérapeutique uniquement aux cellules « malades ». Le ciblage de récepteurs surexprimés par les cellules endothéliales néo-formées, tels que l’intégrine αvβ3, a été envisagé dans le cadre de ce travail grâce à un ligand peptidique c(RGDfK). Ce ciblage associé à l’utilisation d’un complexe photoréactif de RuII permettrait un contrôle du type cellulaire, par la reconnaissance des intégrines αvβ3, ainsi qu’un contrôle temporel de l’activité thérapeutique du complexe, par l’illumination. De manière à combiner ces agents de ciblage et l’agent thérapeutique (complexe de RuII), des plateformes moléculaires de deux types ont été utilisées et comparées entre elles, à savoir le cyclodécapeptide RAFT et un calix[4]arène. La synthèse des conjugués RuII-RAFT-[c-(RGDfK)]4 et le RuII-calix[4]arène-[c-(RGDfK)]4 a donc été réalisée avec succès et leurs propriétés photophysiques et photochimiques ont été étudiées de manière à vérifier que la présence de la plateforme ne modifie pas, Doctorat en Sciences, info:eu-repo/semantics/nonPublished

Human myeloperoxidase (MPO) plays an important role in innate immunity but also aggravates tissue damage by oxidation of biomolecules at sites of inflammation. As a result from a recent high-throughput virtual screening approach for MPO inhibitors, bis-2,2'-[(dihydro-1,3(2H,4H) pyrimidinediyl)bis(methylene)]phenol was detected as a promising lead compound for inhibition of the MPO-typical two-electron oxidation of chloride to hypochlorous acid (IC50 = 0.5 μM). In the present pharmacomodulation study, 37 derivatives of this lead compound were designed and synthesized driven by comprehensive docking studies and the impact on the chlorination activity of MPO. We describe the structural requirements for optimum (i) binding to the heme periphery and (ii) inhibition capacity. Finally, the best three inhibitors (bis-arylalkylamine derivatives) were probed for interaction with the MPO redox intermediates Compound I and Compound II. Determined apparent bimolecular rate constants together with determination of reduction potential and nucleophilicity of the selected compounds allowed us to propose a mechanism of inhibition. The best inhibitor was found to promote the accumulation of inactive form of MPO-Compound II and has IC50 = 54 nM, demonstrating the successful approach of the drug design. Due to the similarity of ligand interactions between MPO and serotonine transporter, the selectivity of this inhibitor was also tested on the serotonin transporter providing a selectivity index of 14 (KiSERT/IC50MPO)., SCOPUS: ar.j, info:eu-repo/semantics/published

BST-2 or tetherin is a host cell restriction factor that prevents the budding of enveloped viruses at the cell surface, thus impairing the viral spread. Several countermeasures to evade this antiviral factor have been positively selected in retroviruses: the human immunodeficiency virus type 2 (HIV-2) relies on the envelope glycoprotein (Env) to overcome BST-2 restriction. The Env gp36 ectodomain seems involved in this anti-tetherin activity, however residues and regions interacting with BST-2 are not clearly defined. Among 32 HIV-2 ROD Env mutants tested, we demonstrated that the asparagine residue at position 659 located in the gp36 ectodomain is mandatory to exert the anti-tetherin function. Viral release assays in cell lines expressing BST-2 showed a loss of viral release ability for the HIV-2 N659D mutant virus compared to the HIV-2 wild type virus. In bst-2 inactivated H9 cells, those differences were lost. Subtilisin treatment of infected cells demonstrated that the N659D mutant was more tethered at the cell surface. Förster resonance energy transfer (FRET) experiments confirmed a direct molecular link between Env and BST-2 and highlighted an inability of the mutant to bind BST-2. We also tested a virus presenting a truncation of 109 amino acids at the C-terminal part of Env, a cytoplasmic tail partial deletion that is spontaneously selected in vitro. Interestingly, viral release assays and FRET experiments indicated that a full Env cytoplasmic tail was essential in BST-2 antagonism. In HIV-2 infected cells, an efficient Env-mediated antagonism of BST-2 is operated through an intermolecular link involving the asparagine 659 residue as well as the C-terminal part of the cytoplasmic tail.

Le cancer du poumon est l’un des cancers les plus fréquents dans le monde et reste le plus meurtrier actuellement en terme d’incidence absolue. Les traitements employés chez les patients atteints d’un cancer du poumon consistent en une combinaison de chirurgie, de radiothérapie et de chimiothérapie. Alors qu’il y a quelques années, les guidelines de traitement étaient principalement basées sur le stade clinique de la maladie, le développement de nouvelles thérapies a mené à une classification plus appropriée des cancers du poumon. Cette nouvelle classification se base, en plus du stade clinique de la maladie, sur l’expression de différents biomarqueurs exprimés chez des sous-populations bien définies de patients. Ces biomarqueurs sont par exemple la mutation d’un gène ou l’expression d’une protéine. Au cours de ces dix dernières années, la recherche a été très active dans ce domaine avec l’arrivée de nouveaux traitements plus spécifiques pour ces sous-populations de patients. Des exemples concrets de ces nouvelles thérapies sont les chimiothérapies dites ciblées et l’immunothérapie. L’arrivée de tels traitements a parmi d’augmenter significativement le pronostic de la maladie et également de réduire considérablement les graves effets secondaires des chimiothérapies conventionnelles. Toutefois, le bénéfice en termes de survie reste modéré. Le taux de survie des patients à cinq ans est actuellement de 15%. Il y a donc toujours un besoin urgent de mettre au point de nouvelles stratégie de traitement.La chimiothérapie inhalée constitue une perspective de traitement adjuvant du cancer du poumon très intéressante, comparée à la chimiothérapie conventionnelle. En effet, elle permettrait d’administrer des doses d’anticancéreux plus importantes directement au niveau du site tumoral tout en limitant l’exposition systémique du médicament dans l’organisme, et donc, les toxicités importantes s’y rapportant. Toutefois, aucun médicament suivant cette approche n’est actuellement di, Lung cancer is one of the most frequent cancers in the world, and remains the most deadly. Lung cancer therapy involves the combination of surgery, radiotherapy and chemotherapy. Whereas the treatment guidelines used to be related mainly to the stage of the disease, more recent treatments have introduced the concept of treating lung cancers according not only to the stage, but also to the specific characteristics of the tumors, i.e. a gene mutation, expression of a protein, etc. In the last decade, scientific and clinical research has been very active in this field, with recurrent introduction of new treatments, including new chemotherapies (e.g. targeted chemotherapies and immunotherapies). Many of these new treatments certainly induce better therapeutic responses and a sharp reduction in the adverse effects of conventional chemotherapies for well-defined subpopulations of patients. However, the benefit in terms of survival rates is only moderate. The five-year survival rate is currently ~15%. There is therefore no doubt that new treatment approaches and strategies are needed. One interesting approach is aerosolized chemotherapy. The pulmonary delivery of anti-cancer drugs could potentially be an interesting alternative to conventional adjuvant chemotherapy in lung cancer treatment, for many reasons. Among them, it could enhance the therapeutic ratio significantly by decreasing systemic severe toxicities and increasing anti-tumour efficacy. However, despite interesting clinical trial reports, all the strategies describing an aerosolized anti-cancer treatment have failed to bring new medicine on the market so far. The failures have been related mainly to (i) the inability to deliver proper and efficient drug doses in the lungs with the inhalation devices used in clinical trials (i.e. nebulizers), (ii) concerns about potential increase in lung toxicities engendered by these anti-cancer drug-based aerosols, and (iii) the requirement for adapted facilities to perform t, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

info:eu-repo/semantics/nonPublished

Metal complexes have been the subject of numerous investigations in oncology but, despite the plethora of newly synthesized compounds, their precise mechanisms of action remain generally unknown or, for the best, incompletely determined. The continuous development of efficient and sensitive techniques in analytical chemistry and molecular biology gives scientists new tools to gather information on how metal complexes can be effective toward cancer. This review focuses on recent findings about the anticancer mechanism of action of metal complexes and how the ligands can be used to tune their pharmacological and physicochemical properties., SCOPUS: re.j, info:eu-repo/semantics/published

Inflammation is the initial response of the body to the harmful stimuli and it is achieved by the increased movement of leukocytes (especially granulocytes) from blood into injured tissues. It is required for healing wounds and infections. Despite their indispensable role in microbial killing, the inflammation reactions may also cause diseases to a host such as hay fever, atherosclerosis, and rheumatoid arthritis. The enzymes and oxidizing species released during the inflammatory process can cause damages to the host tissues which lead to inflammatory syndromes. The role of myeloperoxidase (MPO) in the inflammatory reactions is well documented. It contributes in killing the pathogens but it is also implicated in several inflammatory syndromes such as Parkinson's disease, Alzheimer's disease and atherosclerosis. Thus, this enzyme attracted more and more attention of the scientists and it became a target for drug designing. In the last decade, several reversible and irreversible MPO inhibitors were identified as very high potent inhibitors such as fluoroalkylindole, aromatic hydroxamic acid, thioxanthine and benzoic acid hydrazide derivatives. In this review, we tried to illustrate the MPO inhibitors and highlight their structure activity relationship (SAR). In this paper we also discussed the mechanism of the inhibitory effect of the most potent compounds., SCOPUS: re.j, info:eu-repo/semantics/published

Despite its important role in the immune system, myeloperoxidase (MPO) is implicated in a wide range of inflammatory syndromes due to its oxidative product HOCl. The oxidative damages caused by MPO make it a new target for developing promising anti-inflammatory agents. In this paper, we tried to understand the mechanism of MPO inhibition in order to facilitate the drug design, to develop more accurate virtual tests and to understand the structure-activity relationship., info:eu-repo/semantics/published

Les pathologies infectieuses, maladies causées par certains micro-organismes pathogènes parmi les bactéries, les virus, les champignons et les protozoaires, sont à l’origine des taux de mortalité et de morbidité élevés enregistrés surtout dans les pays en voie de développement où la majorité de la population n’a pas les moyens d'accéder aux soins de santé. Les résistances des micro-organismes aux antimicrobiens, observées actuellement dans la pratique médicale moderne, constituent un autre grand problème lié au traitement de ces maladies. Elles constituent l’une des menaces de santé les plus sérieuses et peuvent frapper n’importe qui dans le monde. Face à ces fléaux, il est urgent de découvrir de nouveaux agents antimicrobiens qui pourraient, éventuellement, présenter de nouveaux mécanismes d'action. Une bonne part des plantes utilisées en médecines traditionnelles contiennent des composants antimicrobiens utiles contre les infections et qui peuvent aider dans la lutte contre les maladies infectieuses liées à l’antibiorésistance. C’est dans cette optique que nous avons mené une enquête ethnobotanique sur les plantes médicinales utilisées contre les infections microbiennes en médecine traditionnelle Burundaise. Nous en avons inventorié 155 et sélectionné 5 d'entre elles (Justicia subsessilis Oliv. (Acanthaceae); Platostoma rotundifolium (Briq.) A. J. Paton (Lamiaceae), Virectaria major (Schum.) Verdc. (Rubiaceae), Pavetta ternifolia (Oliv.) Hiern (Rubiaceae), et Stomatanthes africanus (Oliv. & Hiern) R. M. King & H. Rob. (Asteraceae)) pour en étudier la composition phytochimique et les propriétés biologiques. Les extraits de ces plantes ont été évalués notamment pour leurs effets antibactériens direct (bactéricide ou bactériostatique) et indirect (modulation des mécanismes de résistance qui augmente ou restaure l’activité des antibiotiques sur des souches résistantes). Les cinq plantes retenues ont montré une activité antibactérienne, justifiant ainsi leur usage cont, Infectious pathologies are diseases caused by the transmission of some pathogenic microorganisms among bacteria, viruses, fungi and protozoa. They drive the high mortality and morbidity rates recorded especially in developing countries, where the majority of the population cannot afford to access health care. The antimicrobial resistances currently observed in modern medical practice represent another major problem in the treatment of these diseases. These resistances are one of the most serious population health threats and can strike anyone in the world. It has thus become urgent to discover new antimicrobial agents that could possibly have novel mechanisms of action.Many plants used in traditional medicines against infections harbor useful antimicrobial components that can help in the fight against infectious diseases and antibiotic resistances. In this context, we conducted an ethnobotanical survey of medicinal plants used in Burundian traditional medicine to treat microbial infections. We inventoried 155 herbs from which 5 (Justicia subsessilis Oliv. (Acanthaceae); Platostoma rotundifolium (Briq.) A. J. Paton (Lamiaceae), Virectaria major (Schum.) Verdc. (Rubiaceae), Pavetta ternifolia (Oliv.) Hiern (Rubiaceae), and Stomatanthes africanus (Oliv. & Hiern) R. M. King & H. Rob. (Asteraceae) were selected for phytochemical screening and biological assays. The extracts of these plants were evaluated for their antibacterial effects, direct (bacteriostatic or bactericidal) and indirect (inhibition of resistance mechanisms by increasing or restoring the activity of antibiotics against resistant strains). All the selected plants species have shown antibacterial activity, justifying their use against microbial infections in Burundian traditional medicine, and more particularly Platostoma rotundifolium, whose extracts showed direct and indirect antibacterial effects on susceptible and resistant (MRSA) strains. The extracts from Platostoma rotundifolium also presented inhi, Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie), info:eu-repo/semantics/nonPublished

Platinum-based drugs are commonly used in cancer treatment. The biological activity of a metallodrug is obviously closely related to its chemical and stereochemical characteristics. An overlooked aspect is the effect of the ligand to the electronic structure of the metal atom (coordinated atom). We report herein a Resonant X-ray Emission Spectroscopy (RXES) study on the chemical speciation of chiral platinum complexes in which diastereomers are distinguished on the basis of their metal electronic configuration. This demonstrates RXES high chemical speciation capabilities, a necessary property to further investigate the reactivity of the Pt atom towards nucleophiles or bionucleophiles, and an important complement the previously reported RXES abilities, namely that it can be employed for in situ studies at physiological concentrations., SCOPUS: ar.j, info:eu-repo/semantics/published

Low estradiol level in postmenopausal women is implicated in osteoporosis, which occurs because of the high bone resorption rate. Estrogen formation is controlled by 17-β hydroxysteroid dehydrogenase 17-β HSD enzymes, where 17-β HSD type 1 contributes in the formation of estradiol, while type 2 catalyzes its catabolism. Inhibiting 17-β HSD2 can help in increasing estradiol concentration. Several promising 17-β HSD2 inhibitors that can act at low nanomolar range have been identified. However, there are some specific challenges associated with the application of these compounds. Our review provides an up-to-date summary of the current status and recent progress in the production of 17-β HSD2 inhibitors as well as the future challenges in their clinical application., SCOPUS: re.j, info:eu-repo/semantics/published

This review presents a new application of Resonant X-ray Emission Spectroscopy (RXES) to study the mechanism of action of metal containing anticancer derivatives and in particular platinum in situ and in vivo. The technique is an example of a photon-in photon-out X-ray spectroscopic approach, which enables chemical speciation of drugs to be determined and therefore to derive action mechanisms, and to determine drug binding rates under physiological conditions and therapeutic concentrations. This is made feasible due to the atomic specificity and high penetration depth of RXES. The review presents examples of the three main types of information that can be obtained by RXES and establishes an experimental protocol to perfect the measurements within cells.

The “Journées Franco-Belges de Pharmacochimie” is a recognized two-day annual meeting on Medicinal Chemistry that is renowned for the advanced science presented, conviviality, and outstanding opportunities for senior and young scientists to exchange knowledge. Abstracts of plenary lectures, oral communications, and posters presented during the meeting are collected in this report.